Consensus Syndax Pharmaceuticals, Inc.

Equities

SNDX

US87164F1057

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-19 pm EDT			5-day change	1st Jan Change
20.8 ^USD	+1.51%		-4.24%	-3.75%

Apr. 08	Syndax Pharmaceuticals, Inc. Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session	CI
Mar. 28	Syndax Pharmaceuticals, Inc. Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia	CI

Evolution of the average Target Price on Syndax Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

91686.ZIYk4GhR4fnvdHyZBjAmJLTxUukC-INKoFCqwiYXmD0.ANkXuCEUqYu_EgzGcQFOcdmAFqN7gNss4iHe9EBF9E4l9HaGDROnz6I6RA~4b03e01ccbc1775716cf371a2a67a382

Analyst Recommendations on Syndax Pharmaceuticals, Inc.

JPMorgan Raises Price Target on Syndax Pharmaceuticals to $34 From $31, Maintains Overweight Rating	Mar. 20	MT
Scotiabank Downgrades Syndax Pharmaceuticals to Sector Perform From Sector Outperform, Cuts Price Target to $23 From $36	Jan. 31	MT
JPMorgan Adjusts Syndax Pharmaceuticals Price Target to $37 From $38, Maintains Overweight Rating	Nov. 24	MT
BofA Securities Starts Syndax Pharmaceuticals at Buy With $29 Price Target	23-10-25	MT
Scotiabank Cuts Syndax Pharmaceuticals Price Target to $36 From $39, Maintains Sector Outperform Rating	23-10-03	MT
HC Wainwright Adjusts Syndax Pharmaceuticals Price Target to $42 From $38, Maintains Buy Rating	23-10-02	MT
JPMorgan Adjusts Price Target on Syndax Pharmaceuticals to $33 From $36, Keeps Overweight Rating	23-08-16	MT
Scotiabank Starts Syndax Pharmaceuticals at Sector Perform With $39 Price Target	23-07-27	MT
Barclays Adjusts Price Target on Syndax Pharmaceuticals to $34 From $31, Maintains Overweight Rating	23-07-26	MT
B. Riley Raises Syndax Pharmaceuticals' Price Target to $36 From $34 on Heels of Clinical Update for cGVHD, Keeps Buy Rating	23-07-25	MT
Guggenheim Adjusts Price Target on Syndax Pharmaceuticals to $42 From $40, Maintains Buy Rating	23-07-24	MT
Stifel Adjusts Price Target on Syndax Pharmaceuticals to $38 From $37, Maintains Buy Rating	23-07-24	MT
JPMorgan Adjusts Price Target on Syndax Pharmaceuticals to $36 From $32, Maintains Overweight Rating	23-07-24	MT
HC Wainwright Adjusts Syndax Pharmaceuticals' Price Target to $38 From $36, Keeps Buy Rating	23-07-24	MT
Guggenheim Initiates Syndax Pharmaceuticals With Buy Rating, $40 Price Target	23-07-11	MT
BTIG Adjusts Price Target on Syndax Pharmaceuticals to $35 From $34, Keeps Buy Rating	23-06-26	MT
Citigroup Adjusts Price Target on Syndax Pharmaceuticals to $31 From $32, Keeps Buy Rating	23-05-10	MT
HC Wainwright Adjusts Syndax Pharmaceuticals' Price Target to $36 From $33, Keeps Buy Rating	23-05-09	MT
JPMorgan Adjusts Price Target on Syndax Pharmaceuticals to $36 From $41, Maintains Overweight Rating	23-03-07	MT
Citigroup Adjusts Price Target on Syndax Pharmaceuticals to $32 From $29, Maintains Buy Rating	23-03-02	MT
Goldman Sachs Adjusts Price Target on Syndax Pharmaceuticals to $34 From $39, Maintains Buy Rating	23-03-01	MT
Stifel Starts Syndax Pharmaceuticals at Buy With $37 Price Target	23-01-31	MT
JPMorgan Starts Syndax Pharmaceuticals at Overweight With $41 Price Target	23-01-03	MT
Goldman Sachs Adjusts Price Target on Syndax Pharmaceuticals to $39 From $35, Maintains Buy Rating	22-12-12	MT
HC Wainwright Adjusts Syndax Pharmaceuticals' Price Target to $33 From $31, Keeps Buy Rating	22-12-12	MT